Cargando…
STE029逆转肺腺癌EGFR-TKI耐药及其机制研究
BACKGROUND AND OBJECTIVE: Acquired and primary resistance to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is still the bottleneck of clinical treatment of advanced non-small cell lung cancer (NSCLC). STE029 is a novel anticancer drug which consists of 3-hydroxy-3-methylgluta...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9720680/ https://www.ncbi.nlm.nih.gov/pubmed/36419390 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.46 |